Kindred Bio Announces Initiation of Pivotal Clinical Study for SentiKin™ in Dogs

SentiKin™, KindredBio’s third lead product candidate, is being developed for the treatment of post-operative pain in dogs.

SAN FRANCISCO, California. (March 28, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has initiated the pivotal clinical trial for SentiKin (KIND-009) for post-operative pain in dogs.

Read more

KindredBio Appoints Dr. Blake Hawley as Chief Commercial Officer, Announces Upcoming Inclusion in Russell 2000

Blake Hawley, D.V.M., Worldwide Director of Global Digital and Former General Manager of U.K. & Ireland, Russia, Central Eastern Europe, and Australasia at Hill’s Pet Nutrition, to Join KindredBio

SAN FRANCISCO, California. (March 24, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN) announced today that it has appointed Blake Hawley, D.V.M., as its Chief Commercial Officer. Separately, it also announced that it expects to be added to several Russell indexes on March 31, 2014.

Read more

KindredBio Announces Proposed Public Offering

SAN FRANCISCO, California. (March 18, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed follow-on public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined.

Read more

Kindred Biosciences Announces Fourth Quarter and Year End 2013 Financial Results

San Francisco, CA. (March 6, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the fourth quarter and year ended December 31, 2013. KindredBio will host a webcast and conference call at 1:30 p.m. (PT) this afternoon to review its corporate progress and financial results.

Read more

KindredBio to Present at Roth Capital Partners 26th Annual Growth Stock Conference

SAN FRANCISCO, California. (March 4, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will present at Roth Capital Partners 26th Annual Growth Stock Conference in Dana Point, CA:

Read more

KindredBio Announces Initiation of Pivotal Clinical Study for AtoKin™ in Dogs

AtoKin™, KindredBio’s second lead product, is expected to be a major advance in the treatment of symptoms associated with atopic dermatitis.

SAN FRANCISCO, California. (February 20, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has initiated a pivotal clinical trial for AtoKin (KIND-002) in dogs with atopic dermatitis. The trial is being conducted at veterinary sites across the United States and, if positive, is expected to lead to the approval of AtoKin by 2015.

Read more

KindredBio to Present at 2014 Leerink Global Healthcare Conference

SAN FRANCISCO, California. (February 6, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that members of its senior management team will participate in a fireside chat presentation at the 2014 Leerink Global Healthcare Conference in New York City:

Read more

Kindred Bio Announces Exercise of Over-Allotment Option

SAN FRANCISCO, California. (December 13, 2013) – Kindred Biosciences, Inc. (KindredBio), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that the underwriters of its initial public offering exercised in full their option to purchase up to 1,125,000 additional shares of its common stock at the initial public offering price of $7.00 per share.

Read more

KindredBio Announces Pricing of Initial Public Offering

SAN FRANCISCO, CA, Dec 11, 2013 (Marketwired via COMTEX) — Kindred Biosciences, Inc. (KindredBio), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the pricing of its initial public offering of 7,500,000 shares of its common stock at an initial public offering price of $7.00 per share for a total offering amount of $52,500,000 before deducting underwriting discounts and commissions and estimated offering expenses payable by KindredBio. KindredBio has granted to the underwriters a 30-day option to purchase an additional 1,125,000 shares of its common stock at the initial public offering price. All of the shares are being offered by KindredBio. The shares are expected to begin trading under the ticker “KIN” on the NASDAQ Capital Market on December 12, 2013.

Read more

KindredBio Announces Launch of Initial Public Offering

SAN FRANCISCO, California. (December 2, 2013) – Kindred Biosciences, Inc. (KindredBio), a biopharmaceutical company focused on saving and improving the lives of pets, announced the commencement of its initial public offering of 5,750,000 shares of its common stock, at an anticipated initial public offering price between $6.00 and $8.00 per share. KindredBio also expects to grant the underwriters a 30-day option to purchase up to an additional 862,500 shares of KindredBio’s common stock to cover over-allotments, if any. All shares of the common stock to be sold in the offering will be offered by the Company. KindredBio has applied to list its common stock on the NASDAQ Capital Market under the symbol “KIN.”

Read more